Didn't find what you were looking for?

3D-printed G-EpCAM device effectively captures CTCs to stem metastatic progression. Publications 7 June 2022 ASCO 2022: Extracorporeal microchannel device to capture and eliminate circulating tumor cells from cancer patient’s blood. A 3D-printed G-EpCAM device successfully captured over 85% of CTCs with minimal hemolysis, offering a new way to stem metastatic progression. Background Metastatic progression accounts for nearly 90% of cancer-related deaths and has been directly correlated with the presence of circulating tumor cells (CTCs) in numerous carcinomas, including breast, lung, ovarian, colorectal, and head and neck cancers. The removal of CTCs from cancer patients' blood is directly implicated in the reduction of extravasation and disease invasiveness to secondary organs. Methods We designed and printed 3-dimensional (3D) microchannel devices using a biocompatible polymer and packed them with anti-EpCAM (EpCAM) mediated glass-based (G) compositions (G-EpCAM). Computational fluid dynamic (CFD) analysis simulation was explored to optimize the hemodynamic effect of the G-EpCAM device for measuring the pressure and velocity difference for blood along the spiral flow microchannels. Red blood cell (RBC) hemolysis was estimated using G-EpCAM compositions packed in a device to determine optimal biocompatibility. We assessed cancer cell lines' (breast cancer MCF7, lung cancer A549) interactions and capture with varying incubation time points, the effect of anti-EpCAM concentrations, the number of G-EpCAMs, and series of devices. We evaluated the G-EpCAM-on-device's CTC capture capability and biocompatibility using head and neck, colorectal, lung, and ductal breast cancer patients' blood samples. All G-EpCAM captured CTCs were immunostained for cytokeratin 18 (CK18) expression, and the optimal fluorescence acquisition intensity was quantified. Results The extracorporeal G-EpCAM microchannel device was 3D printed and consisted of an interlocking top lid and bottom base with inlet and outlet channels. The path length of the spiral device consisted of 20 microchannels with a 6.0-foot length. The device accommodated 28 gm of non-hemolytic G-EpCAM compositions. CFD analysis showed 3.8 mm as the ideal channel diameter and 2 mm as the superlative G-EpCAM diameter for maximal cell and CTC capture with minimal blood hemolysis (less than 1%) as compared to the control. Series 1 and 2 devices indicated 90% and 85% cell capture efficiency, respectively, using G-EpCAM devices, indicating the highest interactions and efficiency with cells. Conversely, the first device in the series captured the highest number of cells. In addition, the efficiency improved as the number of G-EpCAM compositions was increased. We accounted for the device to capture CTCs with specificity using the G-EpCAM composition and observed no hemolysis or non-specific interactions with other blood cells like RBCs or leukocytes. Conclusions Continuous CTC removal from cancer patients' blood circulation using such a device offers promising therapeutic utility in stemming aggressive metastatic invasion and progression for improving the overall survival of epithelial origin cancer patients. Clinical Trial Information CTRI U1111/1192-3951. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Magnetically activated nanocellulose enables efficient CTC capture in head & neck cancer. Publications 20 September 2023 Manuscript: Magnetically-activated, nanostructured cellulose for efficient capture of CTCs from the blood sample of head and neck cancer patients Study compares CNC and CNF cellulose nanostructures for EpCAM-based CTC capture in head and neck cancer, enabling affordable real-time cancer monitoring. In this report, the relative efficiency of cellulose nanocrystals (CNCs) and nanofibers (CNFs) to capture circulating tumor cells (CTCs) from the blood samples of head and neck cancer (HNC) patients was evaluated. Detection and enumeration of CTCs are critical for monitoring cancer progression. Both types of nanostructured cellulose were chemically modified with epithelial cell adhesion molecule (EpCAM) antibody and iron oxide nanoparticles. The EpCAM antibody facilitated the engagement of CTCs, promoting their entrapment within the cellulose cage structure. Iron oxide nanoparticles, on the other hand, rendered the cages magnetically activatable, enabling the capture and separation of entrapped CTCs using a magnet. The efficiency of the network structures was demonstrated using blood samples from head and neck cancer patients. It was observed that the degree of chemical functionalization of hydroxyl groups within the CNCs or CNFs with anti-EpCAM determined the efficiency of the system’s interaction with CTCs. Furthermore, the results indicated that the inflexible scaffolds of nanocrystals interacted more efficiently with CTCs than the fibrous CNF scaffolds. Network structures derived from CNCs demonstrated comparable CTC-capturing efficiency to the commercial standard, OncoDiscover®. The findings of this work provide chemical design principles for cellulosic materials intended to construct affordable platforms for monitoring cancer progression in real time. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Explore our Actorius Innovation's Terms & Conditions. Understand your rights and obligations with our comprehensive Terms & Conditions. Terms & Conditions Date Updated: 03 March 2026 Welcome to the official website of Actorius Innovations & Research Pvt. Ltd., accessible at [https://actorius.in ] (the “Website”). By accessing or using this Website, you agree to comply with and be bound by the following Terms and Conditions. Please review them carefully. 1. Acceptance of Terms By accessing, browsing, or using this Website, you acknowledge that you have read, understood, and agreed to be bound by these Terms and Conditions, along with our Privacy Policy. If you do not agree with any part of these terms, you must discontinue use of the Website immediately. 2. Use of the Website The content on this Website is provided for general informational and educational purposes only and is subject to change without prior notice. You agree to use this Website solely for lawful purposes and in a manner that does not infringe the rights of, restrict, or inhibit the use of this Website by any third party. Any unauthorised use, misuse, or abuse of this Website may give rise to a claim for damages and/or be a criminal offence under applicable Indian laws. 3. Intellectual Property Rights All content on this Website, including but not limited to text, graphics, logos, icons, images, illustrations, videos, audio, software, design elements, and data compilations, is the property of Actorius Innovations & Research Pvt. Ltd. or its licensors and is protected by applicable Indian and international intellectual property laws. You may not copy, reproduce, modify, republish, upload, post, transmit, distribute, or exploit any content from this Website in any form or by any means without prior written permission from Actorius Innovations & Research Pvt. Ltd. 4. Third-Party Links This Website may contain links to third-party websites or resources provided for convenience or informational purposes only. Such links do not constitute an endorsement, sponsorship, or recommendation by Actorius Innovations & Research Pvt. Ltd. We have no control over the content, policies, or practices of third-party websites and accept no responsibility or liability for any loss or damage arising from your use of such websites. 5. Disclaimer of Warranties and Limitation of Liability This Website and its content are provided on an “as is” and “as available” basis. Actorius Innovations & Research Pvt. Ltd. makes no representations or warranties, express or implied, regarding the accuracy, completeness, reliability, suitability, or availability of the Website or its content. To the fullest extent permitted by law, Actorius Innovations & Research Pvt. Ltd. shall not be liable for any direct, indirect, incidental, special, consequential, or exemplary damages, including but not limited to loss of profits, data, goodwill, or other intangible losses, arising out of or in connection with your use of, or inability to use, the Website. Nothing in these Terms shall exclude or limit any liability that cannot be excluded under applicable Indian law. 6. Indemnification You agree to indemnify, defend, and hold harmless Actorius Innovations & Research Pvt. Ltd., its directors, officers, employees, affiliates, partners, agents, and licensors from and against any claims, liabilities, damages, losses, costs, or expenses (including reasonable legal fees) arising from: Your use or misuse of the Website Your violation of these Terms and Conditions Your infringement of any intellectual property or other rights of any third party 7. Governing Law and Jurisdiction These Terms and Conditions shall be governed by and construed in accordance with the laws of India. You agree that any disputes arising out of or relating to these Terms or the use of the Website shall be subject to the exclusive jurisdiction of the courts located in [ Pune, Maharashtra, India]. 8. Modifications to Terms Actorius Innovations & Research Pvt. Ltd. reserves the right to revise, modify, or update these Terms and Conditions at any time without prior notice. Any changes will be effective immediately upon posting on the Website. Your continued use of the Website after such changes constitutes acceptance of the revised Terms. 9. Services, Refunds, and Cancellations Where applicable, services offered by Actorius Innovations & Research Pvt. Ltd., including research, diagnostics, analytics, or related scientific and healthcare solutions, are subject to specific terms communicated at the time of engagement. Due to the specialized and scientific nature of our offerings, refunds or cancellations may be limited or not permitted once a service has commenced, data has been processed, or samples/materials have been analyzed. Any requests for cancellation or refund, where applicable, must be submitted in writing through our official communication channels and will be evaluated on a case-by-case basis. 10. Contact Information If you have any questions, concerns, or requests regarding these Terms and Conditions, please contact us at: Actorius Innovations & Research Pvt. Ltd. Website: https://actorius.in/ Contact page: https://actorius.in/contact

OncoDiscover Blood Test Detects Cancer Relapse Early | Dr. Jayant Khandare Expert Insights 28 August 2022 Revolutionary Blood Test Detects Cancer Relapse Early | Dr. Jayant Khandare Discover India's first approved, highly affordable blood test that detects cancer relapse and metastasis earlier than traditional CT or MRI scans. Developed by Dr. Jayant Khandare and clinically validated with Tata Memorial Hospital, this painless test catches circulating tumor cells before it's too late. Cancer relapse and metastasis are responsible for the vast majority of cancer-related fatalities, often because traditional imaging tools like CT and MRI scans fail to catch the disease's return in time. This video highlights a groundbreaking and highly affordable blood test—India's first-in-class medical device approved by the Drug Controller General of India. Developed by Dr. Jayant Khandare, the OncoDiscover test requires only a small volume of blood to identify circulating tumor cells (CTCs) and detect minimal residual disease before it becomes uncontrollable. Clinically validated in partnership with Tata Memorial Hospital in Mumbai, this painless innovation provides oncologists with a powerful tool to monitor patients, optimize treatment, and ensure families never have to hear the dreaded words, "It's too late." Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Dr. Jayant Khandare discusses liquid biopsy on DD Sahyadri interview. Press Release 28 August 2019 Dr. Jayant Khandare – Interview Excerpts on DD Sahyadri Dr. Jayant Khandare shares insights on cancer diagnostics and liquid biopsy advancements in his edited interview on DD Sahyadri, aired by Doordarshan Sahyadri. In this interview, Dr. Jayant Khandare discusses advancements in cancer diagnostics, the growing importance of liquid biopsy technologies, and the need for patient-centric research. He explains the value of early detection in improving survival outcomes and highlights how minimally invasive testing methods can transform cancer care in India. Watch the video Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

TEDx Talk — by Aravindan Vasudevan – CEO, Actorius Innovations and Research Expert Insights 28 February 2023 TEDx Talk — Capturing cancer cells-Uncovering secrets for treatments by Aravindan Vasudevan – CEO, Actorius Innovations Aravindan discusses innovative cancer research in early detection, precision medicine, tumor modeling, and liquid biopsy for advanced cancer insights. Describing cancer cell as the ‘Perfect Villain’ and focusing on how we could help eradicate its conception altogether, Aravindan talks about how they have successfully been able to research and develop various ways to detect early, decode cancer diversity with precision medicine, mimic the tumor microenvironment and liquid biopsy that helps find markers of cancer that has travelled through the bloodstream. Aravindan Vasudevan is the co-founder of Actorius Innovations and Research. At Actorius, Aravindan was part of the team which developed the OncoDiscover – Circulating Tumor Cell Technology, India’s first indigenously developed DCGi approved IVD technology. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. TEDx Talk Link: https://www.ted.com/talks/aravindan_vasudevan_capt Watch video Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

OncoDiscover enables early cancer spread detection and faster diagnosis. | BS Article Press Release 24 August 2019 Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… A team of Pune scientists have discovered a technology that can detect within mere hours, the spread of cancer and claim that the new finding reduces considerably the time taken for detecting the disease. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process. Presently, in India, the final diagnosis report to detect the spread of cancer takes about 12 days whereas, with OncoDiscover technology, doctors can detect it in a mere 3.5 hours. Dr Khandare told ANI, "We felt the need for this technology because global cancer is spreading. 90 per cent of the people get to know they have cancer when it is at the second stage but through this technology, we can try saving that 90 per cent. This technology is needed to detect cancer at an early stage." View full article Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius Innovations at ASCO Annual Meeting 2026 Publications 17 March 2026 ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. Abstract Background Tumor thrombus (TT) refers to the direct extension of tumor cells into a blood vessel and is often detected incidentally. It is commonly observed in renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and Wilms tumor. The presence of TT significantly worsens prognosis and alters disease staging. TT is frequently located in vessels such as the renal vein, inferior vena cava, and portal vein, requiring multidisciplinary evaluation due to its aggressive nature and risk of obstruction or embolization. Diagnostic differentiation between tumor thrombus and a “bland” thrombus (blood clot) typically relies on imaging techniques such as CT or MRI. In this study, we evaluated the association and potential role of circulating tumor cells (CTCs) expressing immune-relevant markers, such as PD-L1, in patients with tumor thrombus. The presence of CTCs originating from TT margins may help refine risk stratification and therapeutic decision-making. Methods In this observational study, 12 patients aged 51–80 years with confirmed tumor thrombus were analyzed. The cohort included patients with hepatocellular carcinoma (HCC, n = 4), pancreatic cancer (n = 3), liver cancer (n = 3), renal cell carcinoma (RCC, n = 1), and gallbladder cancer (GB, n = 1). Blood samples were analyzed for the presence of CTCs with PD-L1 expression at baseline, and three patients also had follow-up samples. Samples were processed using the CDSCO-approved OncoDiscover CTC enrichment technology. CTCs were identified using an automated Zeiss microscope based on EpCAM⁺, CK18⁺, DAPI⁺, CD45⁻, and PD-L1⁺ markers. Results A total of 16 CTCs were detected in 10 patients (83.33%) from 1.5 mL blood samples, with counts ranging from 1 to 6 CTCs per patient. At baseline, patients with HCC, pancreatic, RCC, gallbladder, and other cancers showed the presence of PD-L1–expressing CTCs. Follow-up samples revealed persistent CTC positivity, although the number of PD-L1–positive CTCs decreased. The mean CTC distribution was 1.33 for CK18-expressing CTCs. PD-L1–positive CTCs were detected in a substantial subset, with a mean distribution of 0.67 (9 CTCs among 12 patients), indicating immune-evasive potential. CTC clusters were rare and detected in only one HCC patient but persisted during follow-up. Both male and female patients demonstrated comparable CTC positivity. Conclusion The presence of CTCs in peripheral blood highlights active tumor cell dissemination from tumor thrombus margins. Although CTC clusters were infrequent, their occurrence may indicate an increased metastatic risk. This study demonstrates, for the first time, the presence of CTCs originating from tumor thrombus margins entering systemic circulation. Further studies are required to better understand their clinical implications. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Publications 4 April 2024 Manuscript: CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Study links Shh/Nrf2 overexpression with circulating tumor cells in HNSCC, highlighting their potential as biomarkers for early detection and survival prediction. Background The lack of appropriate prognostic biomarkers remains a significant obstacle in the early detection of Head and Neck Squamous Cell Carcinoma (HNSCC), a cancer type with a high mortality rate. Despite considerable advancements in treatment, the success in diagnosing HNSCC at an early stage still needs to be improved. Nuclear factor erythroid 2-related factor 2 (Nrf2) and Sonic Hedgehog (Shh) are overexpressed in various cancers, including HNSCC, and have recently been proposed as possible therapeutic targets for HNSCC. Circulating Tumor Cell (CTC) is a novel concept used for the early detection of cancers, and studies have suggested that a higher CTC count is associated with the aggressiveness of HNSCC and poor survival rates. Therefore, we aimed to establish molecular markers for the early diagnosis of HNSCC considering Shh/Nrf2 overexpression in the background. In addition, the relation between Shh/Nrf2 and CTCs is still unexplored in HNSCC patients. Methods In the present study, we selected a cohort of 151 HNSCC patients and categorized them as CTC positive or negative based on the presence or absence of CTCs in their peripheral blood. Data on demographic and clinicopathological features with the survival of the patients were analyzed to select the patient cohort to study Shh/Nrf2 expression. Shh and Nrf2 expression was measured by qRT-PCR. Results Considering significant demographic [smoking, betel leaf (p-value < 0.0001)] and clinicopathological risk factors [RBC count (p < 0.05), Platelet count (p < 0.05), Neutrophil count (p < 0.005), MCV (p < 0.0001), NLR (p < 0.05), MLR (p < 0.05)], patients who tested positive for CTC also exhibited significant overexpression of Shh/Nrf2 in both blood and tissue compared to CTC-negative patients. A strong association exists between CTCs and tumor grade. Following chemotherapy (a combination of Cisplatin, 5FU, and Paclitaxel), the frequency of CTCs was significantly decreased in patients with HNSCC who had tested positive for CTCs. The Kaplan–Meier plot illustrated that a higher number of CTCs is associated with poorer overall survival (OS) in patients with HNSCC. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius and ACTREC Partner to Advance Clinical Cancer Research. Press Release 5 February 2026 Actorius and ACTREC Partner to Advance Clinical Cancer Research. A collaborative research initiative to study the practical utility of Circulating Tumor Cells and their capture and depletion from patient's blood as possible aid to adjunct therapeutics. Big step forward for Actorius Innovations and Research 🙌 Actorius recently signed an MOU with Advanced Centre for Treatment, Research and Education in Cancer(ACTREC) to collaborate on clinical studies and research spanning - practical utility of Circulating Tumor Cells and their capture and depletion from patient’s blood as possible aid to adjunct therapeutics. Slowing down or blocking metastasis cascade in early stage patients. Extremely bold and breakthrough innovation hypothesis. This partnership is about taking science closer to patients—generating meaningful real-world evidence, strengthening translational research, and asking the right clinical questions where it truly matters. The MOU was signed by Dr. Pankaj Chaturvedi , Director, ACTREC, and Dr. Jayant Khandare , Co-Founder & CSO, Actorius Innovations and Research. Excited about what lies ahead and the impact this collaboration can create together. Aravindan Vasudevan Rick Kamble Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Automated OncoMetastat device enables CTC removal to support cancer therapy outcomes. Publications 3 November 2025 Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Introduction Despite no radiological evidence of minimal residual disease, up to 25–50% of colorectal cancer (CRC) stage II–III and breast cancer cases experience relapse. Identifying patients at risk of recurrence remains challenging, as approximately 90% of cancer-related deaths are associated with metastasis. The role of circulating tumor cells (CTCs) in extravasation and seeding of distant organs is well established; however, their extracorporeal isolation has not been widely demonstrated in routine practice. Current ex vivo CTC isolation systems often require complex setups and extensive manual handling. In this study, we present an automated device designed to capture and remove CTCs from whole blood using biocompatible cartridges mediated by antibody- and transferrin-conjugated glass bead substrates. Methods We developed the OncoMetastat touchscreen-based operational control device, integrating six roller peristaltic pumps and a cartridge containing 680 targeting 2 mm glass beads functionalized with anti-epithelial cell adhesion molecule (EpCAM) antibodies and transferrin protein. The device housing (365 × 200 × 30 mm) contains a bi-spiral channel (95 × 95 × 10 mm) with 680 beads and eight cross-section channels (3.50 × 3.55 mm). A 3D-printed spring-loaded quick-release mechanism ensures secure tube attachment and rapid cartridge exchange. Flow performance, hemolysis, protein adsorption, and leukocyte interaction were evaluated using blood samples from healthy individuals and cancer patients across multiple cancer types, including breast, CRC, lung, and head and neck cancers. Pyrogenicity was assessed in rabbits according to ISO 10993-11 guidelines. Results The device maintained stable blood circulation at 0.5 mL/min for 5–10 mL whole blood samples using a dual snap-fit holder with a 2° angled offset. The peristaltic pump ensured consistent flow without compromising sample integrity. The bead-filled spiral channel effectively retained CTCs, while the integrated design reduced manual handling and improved reproducibility. Low hemolysis (1%), along with reduced serum protein and leukocyte interactions, was observed in both healthy and cancer patient samples. Selective CTC capture was demonstrated in 24 clinical samples across cancer types. All materials passed pyrogenicity testing, with no temperature elevation observed in accordance with guidelines. Conclusions The OncoMetastat device successfully depleted CTCs from cancer patient whole blood without adversely affecting blood components. The automated system provides stable blood flow and demonstrates proof of performance for extracorporeal CTC removal, with potential to enhance cancer therapy outcomes. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Explore Expert Insights for the latest in Oncology. Discover how Expert Insights shape the domain with cutting-edge knowledge. Expert Insights Insights that shape the domain Deep-dive into expert opinions, scientific perspectives, and thought leadership shaping the future of cancer care. 28 February 2023 TEDx Talk — Capturing cancer cells-Uncovering secrets for treatments by Aravindan Vasudevan – CEO, Actorius Innovations Read More Aravindan discusses innovative cancer research in early detection, precision medicine, tumor modeling, and liquid biopsy for advanced cancer insights. 9 August 20222 OncoDiscover Available in India | Dr. Jayant Khandare Read More OncoDiscover Available in India | Dr. Jayant Khandare 28 August 2022 Revolutionary Blood Test Detects Cancer Relapse Early | Dr. Jayant Khandare Read More Discover India's first approved, highly affordable blood test that detects cancer relapse and metastasis earlier than traditional CT or MRI scans. Developed by Dr. Jayant Khandare and clinically validated with Tata Memorial Hospital, this painless test catches circulating tumor cells before it's too late. 9 August 2022 OncoDiscover Lab Walkthrough Read More OncoDiscover Lab Walkthrough 9 August 2022 Preventing Stage 4 Cancer: India’s Revolutionary Blood Test | Dr. Nirmal Raut Read More Leading oncologists discuss OncoDiscover, India's first indigenous CTC blood test. By detecting Circulating Tumor Cells post-treatment, this affordable "Made in India" innovation catches cancer relapse before it reaches incurable Stage 4, dramatically changing the landscape of cancer care. 9 August 2022 Made in India: The Low-Cost Blood Test Revolutionizing Cancer Care | Dr. Pankaj Chaturvedi Read More Dr. Pankaj Chaturvedi (Director, ACTREC) and Dr. Jayant Khandare discuss OncoDiscover, India's first indigenous CTC blood test. By detecting cancer relapse earlier than traditional scans, this groundbreaking "Made in India" technology drastically lowers patient costs and paves the way for future medical innovations. 11 August 2020 OncoDiscover Liquid Biopsy Technology | Clinical Significance of Circulating Tumor Cell Detection Read More Highlights the clinical value of circulating tumor cell detection using OncoDiscover liquid biopsy technology for cancer diagnosis and patient monitoring. First Prev 1 Page 1 Next Last